You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Large Pore SPP Particles for Protein Separations

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of PEGylated MTI-101 for the treatment of relapsed Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACTModulation Therapeutics is developing a first in class cyclic peptide coined MTIfor the treatment of multiple myelomaThe company currently has a license for the parent molecule which has been awarded a patent covering the intellectual property for both composition of matter and use in cancer in the US and EuropeModulation Therapeutics is now poised to further advance this class of compound ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitisCRSis one of the most prevalent inflammatory diseases in the U Saffecting up toof the population and substantially diminishing the quality of life and productivity of patientsIn four yearsthe annual U Shealth care expenditure to treat patients with CRS dramatically increased from $ B to $Bof the health care budgetwith a corresponding rise in surgical treatment ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: Neuroene Therapeutics, LLC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY GlioblastomaGBMis an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomideTMZEfforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brainIn contrastsensitizing GBM to TMZ is an appealing strategy because TMZ has excelle ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: NIEHS

    Summary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government